Ionpath
- Company typePrivate
- Founded2014
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ionpath does
Ionpath, Inc. is a privately held life-sciences tools company founded in 2014 and headquartered in Menlo Park, California (with an additional Sunnyvale office), that develops and commercializes the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform. The technology uses ion beam mass spectrometry to simultaneously image multiple protein targets in tissue samples while preserving sub-cellular spatial context, addressing limitations of traditional proteomics methods that lose spatial information. The company's core product is the MIBI platform, positioned for translational research and precision medicine applications including disease-mechanism studies and biomarker discovery for targeted therapies.
Ionpath's business model centers on instrument placement and related consumables/antibody panels within the spatial proteomics workflow; source material also references a licensing/royalties-type revenue stream tied to the MIBI technology platform. GTM focus is vertical, targeting translational research cores, academic medical centers, and precision medicine programs, with select_customers not publicly disclosed and pricing not disclosed. The company is included among key players in the Spatial Genomics and Transcriptomics market alongside NanoString Technologies, S2 Genomics, and Akoya Biosciences, addressing a market projected to reach USD 905.4M by 2033.
Strategic capital and commercial validation have come from a syndicate of venture investors led by Genoa Ventures and Samsara BioCapital (2020 $18M round), with prior participation from Bruker, NDCapital, Norwich Ventures, Paladin Partners, Bossa Invest, Trancos Ventures, and Vertical Venture Partners, plus a 2022 strategic investment from Thermo Fisher Scientific. Leadership includes CEO Sander Gubbens, co-founders Mike Angelo and Harris Fienberg, CCO Goran Pljevaljcic, and SVP Marketing & Corporate Strategy Brad Nelson. Total disclosed equity raised is approximately $18M, headcount is 11–50, and the company remains private.
Ionpath firmographics
Firmographics- Name
- Ionpath
- Legal name
- Ionpath, Inc.
- Website
- https://ionpath.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Ionpath industry classification
Industry- Product category
- Spatial Proteomics Instruments & Reagents
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Single-Cell & Spatial Omics Services (HLAGANAC)
- akta.pro secondary industries
- Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI), Translational Medicine & Biomarkers (HLAIALAF), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Ionpath is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ionpath business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Spatial Proteomics Technology Platform: Revenue appears to be generated through MIBI technology platform for spatial proteomics applications in translational research and precision medicine
Ionpath product offering
Product offeringCore offering
Ionpath develops and offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform, a proprietary ion beam imaging technology used to analyze multiple proteins simultaneously in tissue biopsies while preserving spatial context. The platform supports translational research and precision medicine workflows by enabling multiplexed protein analysis that traditional proteomics methods cannot provide.
Product overview
Ionpath offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics technology as its primary product. The MIBI technology enables spatial proteomics analysis for translational research and precision medicine applications.
Differentiator
Problem solved
Functional benefit
Products and services
- MIBI Spatial Proteomics Technology
Companies that use Ionpath
Customer profileSegments2 records
Ideal customer profiles2 records
Ionpath technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Ionpath partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Ionpath competitors and assessment
Company assessmentDirect peers
- Akoya Biosciences: Akoya's CODEX and Phenoptics platforms offer multiplexed spatial proteomics on tissue, directly competing with Ionpath's MIBI in translational and pharma research workflows.
- Standard BioTools: Standard BioTools (formerly Fluidigm) markets the Hyperion imaging mass cytometry system for spatial proteomics, a directly comparable multiplexed tissue-imaging modality to MIBI.
- NanoString Technologies: NanoString's GeoMx digital spatial profiling and CosMx SMI platform compete head-to-head with MIBI in spatial biology and is named alongside Ionpath as a key player in the same market.
- Lunaphore: Lunaphore's COMET platform is a fully automated multiplexed spatial proteomics system, directly comparable to Ionpath's MIBI in tissue-based translational research.
- S2 Genomics: S2 Genomics is named alongside Ionpath as a major player in the spatial genomics and transcriptomics market, with overlapping sample-prep and tissue-handling capabilities.
Broad incumbents
- 10x Genomics: 10x's Xenium and Visium spatial platforms make it a broad incumbent in spatial omics, competing with Ionpath for translational and pharma research dollars even though its core technology differs.
- Bruker: Bruker is an Ionpath investor and offers timsTOF and MALDI imaging mass spectrometry, providing a broader mass-spec-based alternative to MIBI in spatial proteomics.
- Thermo Fisher Scientific: Thermo Fisher made a strategic investment in Ionpath and operates broad life-sciences tools and spatial/imaging workflows that overlap with MIBI's addressable use cases.
- Miltenyi Biotec: Miltenyi's MACSima imaging platform and broader cell-biology portfolio position it as a broad incumbent offering multiplexed tissue imaging alternatives to MIBI.
- Leica Microsystems: Leica (part of Danaher) provides a range of microscopy and tissue-imaging systems used in translational pathology, representing a broader alternative workflow to MIBI-based spatial proteomics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Ionpath social profiles
Digital presenceIonpath financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ionpath leadership team
Management profileNumber of profiles
Profiles6 records
Ionpath funding detail
Funding detailFunding overview
Funding rounds4 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ionpath M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ionpath
What does Ionpath do?
Ionpath develops and offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform, a proprietary ion beam imaging technology used to analyze multiple proteins simultaneously in tissue biopsies while preserving spatial context. The platform supports translational research and precision medicine workflows by enabling multiplexed protein analysis that traditional proteomics methods cannot provide.
Is Ionpath a public or private company?
Ionpath is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ionpath founded?
Ionpath was founded in 2014. It employs 11 to 50 people.
Where is Ionpath based?
Ionpath is headquartered in Menlo Park, United States, in the North America region.
How does Ionpath make money?
One revenue line is on record: spatial Proteomics Technology Platform.
Who are Ionpath's main competitors?
Direct peers on record are Akoya Biosciences, Standard BioTools, NanoString Technologies, Lunaphore and S2 Genomics. Broad incumbents are 10x Genomics, Bruker, Thermo Fisher Scientific, Miltenyi Biotec and Leica Microsystems.
Does Ionpath have an API?
No public API is recorded for Ionpath.
What industry is Ionpath in?
Ionpath's product category is Spatial Proteomics Instruments & Reagents. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers). Its NAICS code is 334516 and its SIC code is 3826.